01:25 PM EDT, 06/18/2025 (MT Newswires) -- Telo Genomics ( TDSGF ) on Wednesday said it initiated a multiple myeloma (MM) clinical trial in collaboration with Cleveland Clinic Cancer Institute, located in Ohio.

The company said samples are to be assessed and stratified between minimal residual disease (MRD) patients that are active or in remission, in a clinical trial of its TeloView MM-MRD assay. The collaboration with Cleveland Clinic allows it to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the U.S., and can contribute to expediting the validation of TeloView MM-MRD.

A statement noted that the collaboration allows for additional research that can validate assays for other utility cases in hematological malignancies, such as TeloView SMM, which is an assay that stratifies patients that are identified as having smoldering MM, a precursor to active MM.

Shares of the company were last seen up $0.005 to $0.08 on the TSX Venture Exchange.

Price: 0.08, Change: +0.01, Percent Change: +6.67